Skip to main content
Top
Published in: Systematic Reviews 1/2016

Open Access 01-12-2016 | Protocol

Economic evidence for the prevention and treatment of atopic eczema: a protocol for a systematic review

Authors: Tracey Helen Sach, Emma McManus, Christopher Mcmonagle, Nick Levell

Published in: Systematic Reviews | Issue 1/2016

Login to get access

Abstract

Background

Eczema, synonymous with atopic eczema or atopic dermatitis, is a chronic skin disease that has a similar impact on health-related quality of life as other chronic diseases. The proposed research aims to provide a comprehensive systematic assessment of the economic evidence base available to inform economic modelling and decision making on interventions to prevent and treat eczema at any stage of the life course. Whilst the Global Resource of Eczema Trials (GREAT) database collects together the effectiveness evidence for eczema, there is currently no such systematic resource on the economics of eczema. It is important to gain an overview of the current state of the art of economic methods in the field of eczema in order to strengthen the economic evidence base further.

Methods/design

The proposed study is a systematic review of the economic evidence surrounding interventions for the prevention and treatment of eczema. Relevant search terms will be used to search MEDLINE, EMBASE, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, National Health Service (NHS) Economic Evaluation Database, Health Technology Assessment, Cumulative Index to Nursing and Allied Health Literature, EconLit, Scopus, Cost-Effectiveness Analysis Registry and Web of Science in order to identify relevant evidence. To be eligible for inclusion studies will be primary empirical studies evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema. Two reviewers will independently assess studies for eligibility and perform data abstraction. Evidence tables will be produced presenting details of study characteristics, costing methods, outcome methods and quality assessment. The methodological quality of studies will be assessed using accepted checklists.

Discussion

The systematic review is being undertaken to identify the type of economic evidence available, summarise the results of the available economic evidence and critically appraise the quality of economic evidence currently available to inform future economic modelling and resource allocation decisions about interventions to prevent or treat eczema. We aim to use the review to offer guidance about how to gather economic evidence in studies of eczema and/or what further research is necessary in order to inform this.

Systematic review registration

PROSPERO CRD42015024633
Appendix
Available only for authorised users
Literature
1.
go back to reference Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. International study of asthma. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947–54.CrossRefPubMed Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. International study of asthma. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947–54.CrossRefPubMed
3.
go back to reference Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–9.CrossRefPubMed Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–9.CrossRefPubMed
5.
go back to reference Schofield JK, Fleming D, Grindlay D, Williams H. Skin conditions are the commonest new reason people present to general practitioners in England and Wales. Br J Dermatol. 2011;165(5):1044–50.CrossRefPubMed Schofield JK, Fleming D, Grindlay D, Williams H. Skin conditions are the commonest new reason people present to general practitioners in England and Wales. Br J Dermatol. 2011;165(5):1044–50.CrossRefPubMed
6.
go back to reference Lewis‐jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–92.CrossRefPubMed Lewis‐jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–92.CrossRefPubMed
7.
go back to reference Paller AS, Mcalister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Paediatr. 2002;41(5):323–32.CrossRef Paller AS, Mcalister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Paediatr. 2002;41(5):323–32.CrossRef
8.
go back to reference Hon KLE, Wang SS, Leung TF. The atopic march: from skin to the airways. Iran J Allergy Asthma Immunol. 2012;11(1):73–7.PubMed Hon KLE, Wang SS, Leung TF. The atopic march: from skin to the airways. Iran J Allergy Asthma Immunol. 2012;11(1):73–7.PubMed
9.
go back to reference Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001;144(3):514–22.CrossRefPubMed Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001;144(3):514–22.CrossRefPubMed
10.
go back to reference Herd RM, Tidman MJ, Prescott RJ, Hunter JAA. The cost of atopic eczema. Br J Dermatol. 1996;135(1):20–3.CrossRefPubMed Herd RM, Tidman MJ, Prescott RJ, Hunter JAA. The cost of atopic eczema. Br J Dermatol. 1996;135(1):20–3.CrossRefPubMed
11.
go back to reference Howell MD, Parker ML, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy. 2015. Howell MD, Parker ML, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy. 2015.
13.
go back to reference Batchelor JM, Ridd MJ, Clarke T, Ahmed A, Cox M, Crowe S, et al. The eczema priority setting partnership: a collaboration between patients, carers, clinicians and researchers to identify and prioritize important research questions for the treatment of eczema. Br J Dermatol. 2013;168(3):577–82.CrossRefPubMed Batchelor JM, Ridd MJ, Clarke T, Ahmed A, Cox M, Crowe S, et al. The eczema priority setting partnership: a collaboration between patients, carers, clinicians and researchers to identify and prioritize important research questions for the treatment of eczema. Br J Dermatol. 2013;168(3):577–82.CrossRefPubMed
15.
go back to reference Nankervis H, Maplethorpe A, Williams HC. Mapping randomized controlled trials of treatments for eczema—the GREAT database (The Global Resource of Eczema Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010). BMC Dermatol. 2011;11(1):10.CrossRefPubMedPubMedCentral Nankervis H, Maplethorpe A, Williams HC. Mapping randomized controlled trials of treatments for eczema—the GREAT database (The Global Resource of Eczema Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010). BMC Dermatol. 2011;11(1):10.CrossRefPubMedPubMedCentral
18.
go back to reference Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.CrossRefPubMed Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.CrossRefPubMed
19.
go back to reference Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://​handbook.​cochrane.​org
20.
go back to reference Centre for reviews and dissemination (CRD). Systematic reviews: CRD’s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination. 2009. Centre for reviews and dissemination (CRD). Systematic reviews: CRD’s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination. 2009.
21.
go back to reference Futamura M, Thomas KS, Grindlay DJ, Doney EJ, Torley D, Williams HC. Mapping systematic reviews on atopic eczema—an essential resource for dermatology professionals and researchers. PLoS ONE. 2013;8(3):58484.CrossRef Futamura M, Thomas KS, Grindlay DJ, Doney EJ, Torley D, Williams HC. Mapping systematic reviews on atopic eczema—an essential resource for dermatology professionals and researchers. PLoS ONE. 2013;8(3):58484.CrossRef
22.
go back to reference Glanville J, Fleetwood K, Yellowlees A, Kaunelis D, Mensinkai S. Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. Glanville J, Fleetwood K, Yellowlees A, Kaunelis D, Mensinkai S. Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
24.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11(1):80.CrossRefPubMedPubMedCentral Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11(1):80.CrossRefPubMedPubMedCentral
25.
go back to reference Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:1–172.CrossRefPubMed Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:1–172.CrossRefPubMed
26.
go back to reference Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics. 2006;24(4):355–71.CrossRefPubMed Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics. 2006;24(4):355–71.CrossRefPubMed
27.
go back to reference Buchanan J, Wordsworth S. Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies? PharmacoEconomics. 2015;33(6):571–9.CrossRefPubMed Buchanan J, Wordsworth S. Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies? PharmacoEconomics. 2015;33(6):571–9.CrossRefPubMed
Metadata
Title
Economic evidence for the prevention and treatment of atopic eczema: a protocol for a systematic review
Authors
Tracey Helen Sach
Emma McManus
Christopher Mcmonagle
Nick Levell
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2016
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-016-0262-0

Other articles of this Issue 1/2016

Systematic Reviews 1/2016 Go to the issue